Literature DB >> 2039211

In vitro synergy studies with Clostridium difficile.

A E Bacon1, S McGrath, R Fekety, W J Holloway.   

Abstract

Agar dilution anaerobic susceptibility studies using rifampin, vancomycin, metronidazole, and bacitracin individually and in combination were performed with Clostridium difficile. Fifty-five strains of C. difficile were studied. Eighty-five percent of strains tested (29 of 34) were synergistically inhibited by the combination of bacitracin and rifampin (fractional inhibitory concentration, less than or equal to 0.50).

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2039211      PMCID： PMC245055          DOI： 10.1128/AAC.35.3.582

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  Cytotoxicity assay in antibiotic-associated colitis.

Authors:  T W Chang; M Lauermann; J G Bartlett
Journal:  J Infect Dis       Date:  1979-11       Impact factor: 5.226

3.  Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens.

Authors:  R Fekety; J Silva; C Kauffman; B Buggy; H G Deery
Journal:  Am J Med       Date:  1989-01       Impact factor: 4.965

4.  The fractional inhibitory concentration (FIC) index as a measure of synergy.

Authors:  M J Hall; R F Middleton; D Westmacott
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

5.  Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients.

Authors:  M Tvede; J Rask-Madsen
Journal:  Lancet       Date:  1989-05-27       Impact factor: 79.321

6.  Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin.

Authors:  G P Young; P B Ward; N Bayley; D Gordon; G Higgins; J A Trapani; M I McDonald; J Labrooy; R Hecker
Journal:  Gastroenterology       Date:  1985-11       Impact factor: 22.682

7.  Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial.

Authors:  M N Dudley; J C McLaughlin; G Carrington; J Frick; C H Nightingale; R Quintiliani
Journal:  Arch Intern Med       Date:  1986-06

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Treatment of Clostridium difficile colitis and diarrhea with vancomycin.

Authors:  J Silva; D H Batts; R Fekety; J F Plouffe; G D Rifkin; I Baird
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

10.  Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin.

Authors:  B P Buggy; R Fekety; J Silva
Journal:  J Clin Gastroenterol       Date:  1987-04       Impact factor: 3.062
  10 in total
  6 in total

1.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013).

Authors:  Stefano Di Bella; Alexander W Friedrich; Esther García-Almodóvar; Maria Serena Gallone; Fabrizio Taglietti; Simone Topino; Vincenzo Galati; Emma Johnson; Silvia D'Arezzo; Nicola Petrosillo
Journal:  BMC Infect Dis       Date:  2015-04-22       Impact factor: 3.090

Review 3.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

4.  Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.

Authors:  Harsh Mathur; Paula M O'Connor; Colin Hill; Paul D Cotter; R Paul Ross
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

Review 5.  Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.

Authors:  Harsh Mathur; Des Field; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2017-06-29       Impact factor: 5.640

6.  The efficacy of thuricin CD, tigecycline, vancomycin, teicoplanin, rifampicin and nitazoxanide, independently and in paired combinations against Clostridium difficile biofilms and planktonic cells.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Gut Pathog       Date:  2016-06-02       Impact factor: 4.181
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.